查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984055

基於電動車的液態生物檢體市場：2026-2032年全球市場預測（按產品類型、技術、疾病、應用和最終用戶分類）

EV-Based Liquid Biopsy Market by Product Type, Technology, Disease Indication, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，基於 EV 的液態生物檢體市場價值將達到 5.5093 億美元，到 2026 年將成長到 6.4181 億美元，到 2032 年將達到 16.9515 億美元，年複合成長率為 17.41%。

主要市場統計數據
基準年 2025 5.5093億美元
預計年份：2026年 6.4181億美元
預測年份：2032年 1,695,150,000 美元
複合年成長率 (%) 17.41%

這是一本簡明扼要、權威性地介紹基於細胞外液態生物檢體的書。說明了其生物學原理、轉化潛力以及目前面臨的操作挑戰。

利用細胞外囊泡（EVs）進行液態生物檢體已從概念研究領域發展成為具有具體臨床轉化應用的實用平台。這些奈米級載體能夠運輸核酸、蛋白質和脂質，為微創觀察腫瘤生物學和全身性疾病狀態提供了一種手段，使臨床醫生和研究人員能夠分析周邊體液中的疾病訊號，而無需完全依賴組織切片檢查。標準化分離技術的出現、檢測化學的改進以及高解析度分析儀器的廣泛應用，逐步降低了技術變異性，並擴展了可分析的生物標記範圍。因此，基於EVs的檢測方法正逐漸成為一種極具吸引力的補充現有分子診斷手段。

技術創新、平台整合和策略合作的整合正在推動基於 EV 的液態生物檢體在臨床和商業性應用方面發生決定性轉變。

基於細胞外囊泡（EV）的診斷領域正經歷著一場變革，這主要得益於分析靈敏度、平台整合和數據驅動解讀等方面的融合進步。新一代定序、定量PCR、高解析度流式細胞技術和奈米顆粒檢測等技術的成熟，使得大規模多重囊泡內容物分析成為可能；同時，標記試劑和分離化學的改進降低了背景噪音，提高了訊號可靠性。因此，研究人員和臨床開發人員正從單一分析物檢測轉向結合核酸和蛋白質檢測的多模態檢測，從而增強了複雜疾病狀態的診斷可靠性。

評估美國於 2025 年推出的新進口關稅對電動車診斷的供應鏈、採購做法和商業化時間表的實際連鎖反應。

2025年實施的關稅措施為電動車診斷設備、耗材和零件的製造商、經銷商和最終用戶帶來了新的挑戰。對於依賴跨境價值鏈的企業而言，進口成本的增加促使它們重新評估籌資策略和商業定價結構。為此，許多相關人員已開始評估各種風險緩解方案，包括重新調整供應商合約、選擇免稅地區的替代供應商以及加快高附加價值零件本地化生產的談判。這些營運調整並非統一實施，導致前置作業時間和採購複雜程度因產品類型和組織結構而異。

詳細的分析揭示了商業性機會和技術重點在設備、耗材、技術、臨床應用、疾病標靶和最終用戶工作流程等方面的集中。

要全面了解基於細胞外囊泡（EV）的液態生物檢體生態系統中的價值和挑戰所在，需要採取嚴謹的、細分化的觀點。從產品類型來看，流式細胞儀、新一代定序系統和定量PCR儀等儀器和平台構成了高性能臨床級分析的基礎。同時，檢測試劑、分離液和標記劑等試劑盒和試劑則確保了檢測的可重複性和標準化。包括分析工作流程和樣本製備服務在內的各種服務，可以彌補實驗室內部處理能力和檢查室專業知識的不足。每個產品子類別都需要不同的驗證途徑和商業性策略才能實現常規臨床應用。

一項基於區域背景的分析，將美洲、歐洲、中東、非洲和亞太地區的研究生態系統、監管細微差別、製造能力和臨床網路連接起來。

區域趨勢對基於細胞外囊泡（EV）的液態生物檢體解決方案的開發、部署和商業化策略有顯著影響。在美洲，完善的轉化研究基礎設施和活躍的臨床試驗為早期臨床檢驗提供了有利條件；然而，不同地區在報銷管道和採購週期上的差異，使得制定針對特定區域的證據生成策略成為必要。歐洲、中東和非洲的法規環境較為複雜，既有集中式的法規結構，也有各國特有的報銷機制。因此，掌握當地法規並與區域診斷實驗室建立策略夥伴關係關係，對於市場進入和擴張至關重要。在亞太地區，快速成長的研發投入、不斷提升的分子診斷能力以及具有競爭力的在地化生產，共同推動了創新和成本驅動部署模式的快速迭代。

這項關鍵的競爭分析重點介紹了儀器 OEM 廠商、試劑創新者、平台Start-Ups和服務實驗室如何塑造其商業化、夥伴關係和臨床檢驗策略。

基於電動車的液態生物檢體領域的競爭格局呈現出多元化的特點，既有成熟的儀器製造商，也有專業的試劑盒供應商、創新平台Start-Ups，以及提供高度複雜檢測的服務實驗室。市場領導者透過整合檢驗的硬體、應用專用試劑和數據分析，打造整合解決方案，進而降低診斷實驗室和醫療機構的臨床應用門檻。新興企業則專注於自身優勢領域，例如改進的分離化學技術、專有的標記試劑或高靈敏度的奈米顆粒檢測技術，這些技術可以授權使用或整合到大規模的平台生態系統中。

為高階主管提供可操作且優先考慮的建議，以加強臨床應用、保障供應鏈、產生與支付方相關的證據，並加速基於電動車的診斷的商業化。

產業領導者應採取務實且基於實證的策略，平衡短期業務永續營運和中期臨床整合。首先，應優先降低樣本製備過程中的變異性，投資於檢驗的檢體採集和分離通訊協定，這些方案可以與設備捆綁銷售或作為認證服務提供，從而加快檢查室部署。其次，應實現供應鏈多元化，並促進關鍵組件的選擇性本地化，以降低貿易中斷風險，並確保監管管道和品質系統到位，從而支援本地化生產，避免檢驗延誤。第三，應開發整合的商業提案，將平台與檢驗的試劑盒和分析流程結合，以簡化醫院和診斷實驗室的採購決策。

結合相關人員訪談、技術文獻整合、監管審查和專家檢驗，採用穩健的多方面調查方法，確保獲得可靠且可操作的見解。

本分析所依據的研究整合了來自多方面的證據，旨在交叉檢驗技術趨勢、商業性趨勢和監管模式。主要資訊來源包括相關人員（儀器開發人員、試劑生產商、實驗室管理人員、轉化研究人員和監管顧問）的結構化訪談，以及近期平台應用和臨床檢驗工作的案例。次要分析則納入了同行評審文獻、監管指導文件、臨床實驗室註冊數據和企業資訊披露，以梳理技術能力、產品線和戰略趨勢。

一項綜合分析，旨在確定技術可能性、操作限制和戰略挑戰，以便將基於 EV 的液態生物檢體的進步轉化為永續的臨床和商業性成果。

基於細胞外囊泡（EV）的液態生物檢體代表了一個引人入勝的領域，它融合了分子生物學、儀器工程和臨床應用。這項技術正迅速發展，並呈現出整合平台、檢驗的試劑組和外包分析服務發展的明顯趨勢，這些措施共同降低了部署的營運負擔。儘管科學進步提升了分析能力，但諸如預分析階段的標準化、供應鏈的韌性以及支付方的證據要件等實際限制仍然是決定這些檢測方法能否快速應用於常規臨床實踐的關鍵因素。透過協作式證據產生、互通平台和策略性供應鏈在地化來解決這些限制的產業相關人員，更有可能獲得臨床夥伴關係關係和長期商業性價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：基於電動車的液態生物檢體市場：按產品類型分類

  • 設備和平台
    • 流式細胞儀
    • NGS平台
    • qPCR裝置
  • 試劑盒和試劑
    • 檢測套件
    • 分離套件
    • 標記試劑
  • 服務
    • 分析服務
    • 樣品製備服務

第9章：基於電動車的液態生物檢體市場：按技術分類

  • ELISA
  • 流式細胞技術
  • 微陣列
  • 奈米顆粒檢測
  • NGS
  • qPCR

第10章：基於細胞外囊泡的液態生物檢體市場：依疾病分類

  • 乳癌
  • 結腸癌
  • 肺癌
  • 攝護腺癌

第11章 基於電動車的液態生物檢體市場：按應用領域分類

  • 伴隨診斷
  • 癌症早期發現
  • 預後和監測
  • 研究

第12章 基於電動車的液態生物檢體市場：按最終用戶分類

  • 診斷實驗室
  • 醫院和診所
  • 製藥公司
  • 研究機構

第13章：基於電動車的液態生物檢體市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 以電動車為基礎的液態生物檢體市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：基於電動車的液態生物檢體市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國電動車液態生物檢體市場

第17章：中國電動車液態生物檢體市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abcam PLC
  • Agena Bioscience
  • Agilent Technologies, Inc.
  • ALS Automated Lab Solutions GmbH
  • ANGLE PLC
  • Bio-Rad Laboratories, Inc
  • Bio-Techne Corporation
  • BioFluidica
  • Biological Dynamics
  • Bristol-Myers Squibb
  • CH Boehringer Sohn AG & Co. KG
  • Clinomics Europe Ltd.
  • Corning Incorporated
  • ExosomeDx
  • Horiba Ltd.
  • Illumina, Inc.
  • Lonza Group Ltd.
  • Malvern Panalytical Ltd.
  • Mercy BioAnalytics, Inc.
  • MoBiTec GmbH by BIOZOL Diagnostica Vertrieb GmbH
  • Mursla Bio
  • Nanostics Inc.
  • PerkinElmer, Inc.
  • Qiagen NV
  • Quest Diagnostics
  • System Biosciences, LLC
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-2E76C3E47F69

The EV-Based Liquid Biopsy Market was valued at USD 550.93 million in 2025 and is projected to grow to USD 641.81 million in 2026, with a CAGR of 17.41%, reaching USD 1,695.15 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 550.93 million
Estimated Year [2026] USD 641.81 million
Forecast Year [2032] USD 1,695.15 million
CAGR (%) 17.41%

Concise and authoritative introduction to extracellular vesicle liquid biopsies, explaining biological basis, translational promise, and current operational challenges

Extracellular vesicle-based liquid biopsy has evolved from a conceptual research area into a pragmatic platform with tangible clinical and translational applications. These nanoscale carriers of nucleic acids, proteins, and lipids offer a minimally invasive window into tumor biology and systemic disease states, enabling clinicians and researchers to interrogate disease signals from peripheral fluids rather than relying exclusively on tissue biopsies. The emergence of standardized isolation techniques, improved detection chemistries, and higher-resolution analytic instrumentation has progressively reduced technical variability and expanded the range of interrogable biomarkers, positioning EV-based assays as an attractive complement to established molecular diagnostics.

Despite clear promise, the field navigates a set of scientific and operational constraints that temper rapid clinical adoption. Harmonization of pre-analytical workflows, including sample collection, stabilization, and isolation, remains a priority to ensure reproducible results across sites and platforms. Concurrently, the development of robust analytical pipelines-with sensitivity sufficient to detect low-abundance vesicle populations and specificity to attribute cargo to disease-relevant processes-continues to be an area of concentrated innovation. Regulatory scrutiny and payer engagement are gradually aligning around evidentiary expectations, and as translational studies accumulate, the most compelling use cases for companion diagnostics, early cancer detection, and disease monitoring are becoming more clearly defined. The introduction of modular instrument platforms, dedicated reagent kits, and outsourced analytical services is helping to bridge early translational work with clinical workflows, creating pragmatic pathways for wider implementation.

How converging technological innovations, platform integration, and strategic partnerships are driving a decisive transformation in EV-based liquid biopsy clinical and commercial adoption

The landscape of EV-based diagnostics is undergoing transformative shifts driven by convergent advances in analytical sensitivity, platform integration, and data-driven interpretation. Technological maturation across next-generation sequencing, quantitative PCR, high-resolution flow cytometry, and nanoparticle assays is enabling multiplexed characterization of vesicle cargo at scale, while improved labeling reagents and isolation chemistries reduce background noise and enhance signal fidelity. As a result, researchers and clinical developers are pivoting from single-analyte concepts to multimodal assays that combine nucleic acid and protein readouts, which strengthens diagnostic confidence for complex disease states.

Commercial models are also evolving: instrument manufacturers increasingly offer integrated platforms that pair hardware with validated kits and cloud-based analytics, reducing the time and technical expertise required to operationalize assays in diagnostic laboratories. Service providers specializing in sample preparation and high-throughput analytics are expanding partnerships with academic medical centers and pharmaceutical developers, accelerating translation from cohort studies to clinical trials. In parallel, strategic alliances between platform firms and clinical networks are creating adoption pathways that prioritize clinical validation and reimbursement readiness. Together, these shifts are streamlining the progression from discovery to clinical utility and reshaping competitive dynamics across technology vendors, reagent suppliers, and service laboratories.

Assessment of the practical ripple effects that new United States import tariffs introduced in 2025 have generated across supply chains, procurement practices, and commercialization timelines for EV-based diagnostics

Tariff measures instituted in 2025 have introduced new considerations for manufacturers, distributors, and end users of EV-based diagnostic instruments, consumables, and components. For firms that rely on cross-border supply chains, increased import costs have prompted a reassessment of procurement strategies and commercial pricing structures. In response, many stakeholders began to evaluate options to mitigate exposure, including re-indexing supplier contracts, qualifying alternative vendors in tariff-exempt jurisdictions, and accelerating negotiations to localize production of high-value components. These operational adjustments have not been uniform, producing variance in lead times and procurement complexity across different product segments and organizational types.

Clinical laboratories and service providers have felt the operational friction in the form of longer replenishment cycles and selective prioritization of capital expenditures, which in turn affects rollout schedules for new assays. Conversely, the tariff environment has galvanized investment in domestic manufacturing capabilities and contract manufacturing relationships aimed at strategic resilience. For instrument OEMs, the need to preserve margin has driven a mix of cost engineering and reconfiguration of bundled offerings, often emphasizing consumable-based revenue streams to offset capital cost pressures. Importantly, regulatory and quality compliance requirements continue to govern the feasibility and speed of onshoring initiatives, so companies pursuing localization must integrate regulatory pathways into supply chain planning to avoid introducing downstream validation delays.

Deep segmentation-driven insights revealing where instruments, consumables, technologies, clinical applications, disease focus, and end-user workflows concentrate commercial opportunity and technical priority

A rigorous segmentation-aware perspective is essential to understand where value and friction reside across the EV-based liquid biopsy ecosystem. From a product-type viewpoint, instruments and platforms-spanning flow cytometers, next-generation sequencing systems, and quantitative PCR units-serve as the backbone for high-throughput and clinical-grade analytics, while kits and reagents such as detection chemistries, isolation solutions, and labeling agents enable assay reproducibility and standardization. Services, including analytical workflows and sample preparation offerings, bridge capability gaps for laboratories that lack in-house throughput or validation expertise. Each of these product subcategories requires different validation pathways and commercial approaches to reach routine clinical deployment.

Technology segmentation reveals differentiated roles for ELISA and microarray approaches in protein-level characterization, flow cytometry and nanoparticle assays for vesicle phenotyping, and NGS and qPCR for nucleic acid profiling. Application-level insights indicate that companion diagnostics and early cancer detection are driving demand for high analytical sensitivity and clinical-grade validation, whereas prognosis, monitoring, and research use cases prioritize longitudinal sampling, throughput, and cost-effectiveness. Disease-indication focus areas-breast, colorectal, lung, and prostate cancers-exhibit distinct biomarker signatures and clinical workflows, creating opportunities for indication-specific assay development and targeted validation studies. End-user segmentation underscores the variety of operational contexts: diagnostic laboratories and hospital networks demand robust, reproducible solutions with clear integration pathways into laboratory information systems, pharmaceutical companies seek scalable assays for trial stratification and pharmacodynamic readouts, and research centers prioritize flexibility and depth of molecular characterization. Taken together, these segmentation dimensions highlight where commercial strategies should concentrate: enabling platform interoperability, standardizing pre-analytical steps, and aligning service offerings with the differing validation timelines and throughput requirements of end users.

Contextualized regional analysis that links research ecosystems, regulatory nuance, manufacturing capacity, and clinical networks across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence the development, adoption, and commercial strategies for EV-based liquid biopsy solutions. In the Americas, robust translational research infrastructure and significant clinical trial activity create fertile ground for early clinical validation, yet reimbursement pathways and procurement cycles can vary regionally, requiring tailored evidence-generation strategies. Europe, the Middle East & Africa present a heterogeneous regulatory environment where centralized regulatory frameworks coexist with country-specific reimbursement mechanisms, making localized regulatory expertise and strategic partnerships with regional diagnostics labs critical for market entry and scale. In the Asia-Pacific region, fast-growing R&D investment, expanding molecular diagnostics capacity, and competitive local manufacturing contribute to rapid iterative cycles of innovation and cost-sensitive adoption models.

Across these regions, the availability of specialized service laboratories, proximity to manufacturing clusters, and the maturity of clinical networks shape the commercial playbook. Stakeholders should therefore align regulatory planning, clinical partnerships, and supply chain design with regional strengths, while anticipating cross-border logistical considerations that affect reagent shelf life and instrument servicing. Regional collaboration, such as multinational validation studies and shared reference standards, can reduce duplicative effort and accelerate broader clinical acceptance, but success hinges on careful orchestration of local regulatory and clinical stakeholders.

Critical competitive analysis highlighting how instrument OEMs, reagent innovators, platform start-ups, and service laboratories are shaping commercialization, partnerships, and clinical validation strategies

Competitive dynamics in the EV-based liquid biopsy sector are defined by a mix of established instrument manufacturers, specialized reagent and kit providers, innovative platform start-ups, and service laboratories offering high-complexity testing. Market leaders tend to differentiate through integrated offerings that combine validated hardware, application-specific reagents, and data analytics, thereby lowering the barrier to clinical adoption for diagnostic laboratories and healthcare providers. Emerging companies focus on niche strengths-such as enhanced isolation chemistries, proprietary labeling reagents, or high-sensitivity nanoparticle detection technologies-that can be licensed or bundled into larger platform ecosystems.

Strategic behaviors worth noting include the formation of co-development partnerships with clinical networks and pharmaceutical sponsors to accelerate clinical validation; licensing agreements that expand distribution reach without diluting technical differentiation; and investments in cloud-based analytics and standards development to underpin cross-platform comparability. Service providers that offer standardized sample preparation and centralized analytics are increasingly important as clinical studies scale, and they often serve as the translation conduit between exploratory research and regulated diagnostics. For established players, defending technological moats through IP, scaling manufacturing capabilities, and constructing reimbursement-ready clinical evidence are the primary levers for maintaining competitive advantage.

Actionable and prioritized recommendations for executives to strengthen clinical adoption, secure supply chains, generate payer-relevant evidence, and accelerate commercialization of EV-based diagnostics

Industry leaders should adopt a pragmatic, evidence-focused strategy that balances near-term operational resilience with mid-term clinical integration. First, prioritize the reduction of pre-analytical variability by investing in validated sample collection and isolation protocols that can be packaged with instruments or offered as certified services, thereby accelerating laboratory uptake. Second, diversify supply chains and pursue selective localization of key components to reduce exposure to trade disruptions while ensuring that regulatory pathways and quality systems are in place to support onshoring without introducing validation delays. Third, develop integrated commercial propositions that pair platforms with validated kits and analytic pipelines to simplify procurement decisions for hospitals and diagnostic laboratories.

Moreover, stakeholders should proactively engage payers and clinical opinion leaders early in translational studies to identify the evidence endpoints that matter for reimbursement and clinical guideline inclusion. Strategic collaborations with pharmaceutical companies for companion diagnostic development can deliver mutual value through co-funded validation studies. Finally, invest in analytical interoperability and data standards to enable cross-platform comparability, and build service offerings that support laboratories transitioning to higher-throughput EV assays. These actions, taken together, will create defensible differentiation and reduce barriers to scale.

Robust multi-method research methodology combining stakeholder interviews, technical literature synthesis, regulatory review, and expert validation to ensure credible and actionable insights

The research behind this analysis synthesized evidence from a multi-method approach designed to triangulate technical trends, commercial behaviors, and regulatory patterns. Primary inputs included structured interviews with stakeholders across the value chain-instrument developers, reagent manufacturers, clinical laboratory directors, translational researchers, and regulatory consultants-combined with case studies of recent platform deployments and clinical validation efforts. Secondary analysis incorporated peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to map technological capabilities, product offerings, and strategic moves.

Findings were validated through expert panels that reviewed key assumptions and interpretation of technical trade-offs, and results were subjected to internal quality checks to ensure consistency and minimize bias. Segmentation frameworks were constructed to reflect product, technology, application, disease indication, and end-user distinctions, and regional analysis incorporated variations in regulatory frameworks and clinical infrastructure. Where possible, methodological transparency was maintained by documenting inclusion criteria for studies and interviews, the timeframe of evidence collection, and the rationale for weighting different types of input when forming strategic conclusions.

Concluding synthesis that distills technical promise, operational constraints, and strategic imperatives to convert EV-based liquid biopsy advances into durable clinical and commercial outcomes

EV-based liquid biopsy represents a compelling intersection of molecular biology, instrumentation engineering, and clinical ambition. The technology suite continues to evolve rapidly, with clear momentum toward integrated platforms, validated reagent kits, and outsourced analytical services that together reduce the operational burdens of adoption. While scientific advances have sharpened analytical capabilities, pragmatic constraints-such as pre-analytical standardization, supply chain resilience, and payer evidentiary requirements-remain the principal determinants of how quickly these assays enter routine clinical practice. Industry actors that address these constraints through coordinated evidence generation, interoperable platforms, and strategic localization of supply will be best positioned to capture clinical partnerships and long-term commercial value.

Looking ahead, the balance between specialization and integration will define competitive trajectories: companies that deliver clinically validated, easy-to-deploy solutions will lower adoption friction for healthcare providers, whereas those that focus on niche innovations will play critical roles as technology enablers. For decision-makers, the immediate imperative is to align technical development with realistic clinical validation pathways and to design commercial models that reflect the operational realities of diagnostic laboratories and healthcare systems. By doing so, stakeholders can translate scientific potential into clinically actionable diagnostics that improve patient care and support precision medicine objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. EV-Based Liquid Biopsy Market, by Product Type

  • 8.1. Instruments And Platforms
    • 8.1.1. Flow Cytometers
    • 8.1.2. NGS Platforms
    • 8.1.3. qPCR Instruments
  • 8.2. Kits And Reagents
    • 8.2.1. Detection Kits
    • 8.2.2. Isolation Kits
    • 8.2.3. Labeling Reagents
  • 8.3. Services
    • 8.3.1. Analytical Services
    • 8.3.2. Sample Preparation Services

9. EV-Based Liquid Biopsy Market, by Technology

  • 9.1. ELISA
  • 9.2. Flow Cytometry
  • 9.3. Microarray
  • 9.4. Nanoparticle Assays
  • 9.5. NGS
  • 9.6. qPCR

10. EV-Based Liquid Biopsy Market, by Disease Indication

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Lung Cancer
  • 10.4. Prostate Cancer

11. EV-Based Liquid Biopsy Market, by Application

  • 11.1. Companion Diagnostics
  • 11.2. Early Cancer Detection
  • 11.3. Prognosis And Monitoring
  • 11.4. Research

12. EV-Based Liquid Biopsy Market, by End User

  • 12.1. Diagnostic Laboratories
  • 12.2. Hospitals And Clinics
  • 12.3. Pharmaceutical Companies
  • 12.4. Research Centers

13. EV-Based Liquid Biopsy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. EV-Based Liquid Biopsy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. EV-Based Liquid Biopsy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States EV-Based Liquid Biopsy Market

17. China EV-Based Liquid Biopsy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abcam PLC
  • 18.6. Agena Bioscience
  • 18.7. Agilent Technologies, Inc.
  • 18.8. ALS Automated Lab Solutions GmbH
  • 18.9. ANGLE PLC
  • 18.10. Bio-Rad Laboratories, Inc
  • 18.11. Bio-Techne Corporation
  • 18.12. BioFluidica
  • 18.13. Biological Dynamics
  • 18.14. Bristol-Myers Squibb
  • 18.15. C.H. Boehringer Sohn AG & Co. KG
  • 18.16. Clinomics Europe Ltd.
  • 18.17. Corning Incorporated
  • 18.18. ExosomeDx
  • 18.19. Horiba Ltd.
  • 18.20. Illumina, Inc.
  • 18.21. Lonza Group Ltd.
  • 18.22. Malvern Panalytical Ltd.
  • 18.23. Mercy BioAnalytics, Inc.
  • 18.24. MoBiTec GmbH by BIOZOL Diagnostica Vertrieb GmbH
  • 18.25. Mursla Bio
  • 18.26. Nanostics Inc.
  • 18.27. PerkinElmer, Inc.
  • 18.28. Qiagen N.V.
  • 18.29. Quest Diagnostics
  • 18.30. System Biosciences, LLC
  • 18.31. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EV-BASED LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EV-BASED LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY NGS PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY NGS PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY NGS PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY QPCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY QPCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY QPCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY DETECTION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY DETECTION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY DETECTION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY ISOLATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY ISOLATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY ISOLATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY LABELING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY LABELING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY LABELING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY NANOPARTICLE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY NANOPARTICLE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY NANOPARTICLE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PROGNOSIS AND MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PROGNOSIS AND MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PROGNOSIS AND MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 184. GCC EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. GCC EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. G7 EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 212. G7 EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. NATO EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 219. NATO EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 221. NATO EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL EV-BASED LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS AND PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA EV-BASED LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)